Curated News
By: NewsRamp Editorial Staff
October 02, 2026
Blood Samples Could Replace Tumor Biopsies for Personalized Immunotherapy
TLDR
- Blood-based immunotherapy profiling could speed treatment development for companies like Calidi Biotherapeutics Inc. by reducing reliance on surgical tumor samples.
- The blood-based approach analyzes cancer neoantigens and T-cell activation to potentially replace surgical tumor sampling for personalized immunotherapy manufacturing.
- Patients with hard-to-access tumors may soon avoid risky surgery, as blood samples could enable personalized cancer treatment for more people.
- Scientists are exploring whether a simple blood draw can reveal the cancer-specific proteins needed to create personalized immunotherapies.
Impact - Why it Matters
This development could significantly broaden the reach of personalized cancer treatments. For patients with inoperable tumors or those too frail for surgery, a blood-based method would eliminate a major barrier to receiving tailored immunotherapies. It could also speed up the manufacturing process, allowing therapies to be developed more quickly and at lower risk. If validated, this approach could transform the standard of care in oncology, making precision medicine accessible to a wider population and enabling more dynamic treatment adjustments as tumors mutate.
Summary
Immunotherapy, a form of personalized cancer treatment, currently requires a tumor sample to be removed surgically and analyzed so that the personalized treatment needed by the patient can be manufactured. However, getting the needed tumor sample can be challenging in many patients, such as those with tumors in hard-to-access parts of the body or those whose physical condition makes it risky to have surgery done to extract a sample. This limitation has spurred interest in less invasive methods, and recent research suggests that blood samples could serve as a viable alternative source for identifying cancer-specific proteins and T-cell activation, potentially streamlining the development of personalized immunotherapies.
If additional clinical trials confirm the efficacy of the blood-based approach to obtaining data on cancer neoantigens and specific T-cell activation, the method could potentially reduce the time that is required to manufacture immunotherapies developed by entities like Calidi Biotherapeutics Inc. (NYSE American: CLDI). This could accelerate treatment timelines and expand access for patients who currently face barriers to obtaining tumor samples. The approach may also enable more frequent monitoring and adaptation of therapies as tumors evolve.
The news was distributed by BioMedWire (“BMW”), a specialized communications platform focused on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Blood Samples Could Replace Tumor Biopsies for Personalized Immunotherapy
